丹参酮ⅡA磺酸钠注射液与辛伐他汀协同对冠心病患者炎症因子的影响

Influence of Tanshinone ⅡA Sulfonate Injection Combined with Simvastatin on Inflammatory Factor in Patients with Coronary Heart Disease

目的探讨丹参酮IIA磺酸钠与辛伐他汀协同对冠心病患者炎症因子的影响。方法将150例冠心病患者随机分为治疗组A50例、治疗组B50例和对照组50例。对照组给予硝酸酯类、阿司匹林等常规治疗,并给予辛伐他汀20 mg口服,每晚1次,治疗组在对照组基础上加用丹参酮IIA磺酸钠注射液,其中治疗组A加用40 mg,治疗组B加用80 mg,疗程14天。结果治疗结束后,治疗组A与治疗组B的有效率显著高于对照组(P<0.01)。与治疗组A比较,治疗组B有效率显著提高(P<0.05);与治疗前比较,3组治疗后hs-CRP水平均有统计学差异(P<0.01,或P<0.05);与对照组治疗后比较,治疗组B血清hs-CRP水平显著降低,差异具有统计学意义(P<0.05)。结论他汀类药具有抗血管炎症反应作用,与丹参酮ⅡA配合使用,对冠心病患者炎症因子抑制反应更加显著。

OBJECTIVE To explore tanshinone IIA sulfonate injection combined with simvastatin on inflammatory factor in patients with coronary heart disease （CHD）. METHODS A total of 150 patients with CHD were divided into treatment group A（50 cases）, treatment group B（50 cases） and control group（50 cases）. Treatment groups were given nitrate esters, aspirin and oral simvastatin（20 rag）, once every night, based on which, treatment group A was given 40 mg of tanshinone IIA sulfonate injection and treatment B was given 80 mg of tanshinone IIA sulfonate injection, 14 d as one cycle. RESULTS After the treatment, the total effective rates of treatment groups were higher than control group（P〈0.01）. And treatment group B was higher than treatment group A（P〈0.05）. The level of hs-CRP of 3 groups after treatment were lower than treatment before（P〈0.01, P〈0.05）. After treatment, compared with control group, the level of hs-CRP in treatment group B decreased （P〈0.05）. CONCLUSION Statins has effect against vascular in- flammation and combined with Tanshinone IIA, was effective in inhibiting inflammatory factor for patients with CHD.